STOCK TITAN
  1. Home
  2. News
  3. BMRN

BioMarin to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
  • Credit Suisse 31st Annual Healthcare Conference 2022: November 8th, 8:35amPT/11:35amET, in Rancho Palos Verdes, CA
  • 13th Annual Jefferies Global Healthcare Conference 2022: November 16th, 8:35amGMT, in London, England

SAN RAFAEL, Calif., Nov. 3, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at two upcoming investor conferences. To access the live webcasts, please visit: https://investors.biomarin.com/.  An archived version of the presentations will also be available through the Company's website for a limited time following the conference.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

415) 455-7451

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-investor-conferences-301667428.html

SOURCE BioMarin Pharmaceutical Inc.

Stock BMRN logo
BioMarin Pharmaceuticals Inc

NASDAQ:BMRN

BMRN Rankings

#613 Ranked by Market Cap
#2446 Ranked by Stock Gains
N/A Ranked by Dividends

BMRN Latest News

Apr 24, 2024
BioMarin Reports Record Financial Results for the First Quarter 2024
Apr 10, 2024
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
Mar 12, 2024
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Mar 7, 2024
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Mar 1, 2024
BioMarin Scheduled to Participate in March Investor Conferences

BMRN Stock Data

15.33B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NOVATO

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment